April 18 (Reuters) - Heron Therapeutics Inc :
* Heron Therapeutics provides update on FDA review of Sustol NDA
* FDA has indicated that there are no substantive deficiencies in NDA for Sustol injection
* FDA has begun labeling discussions with company Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
Our Standards: The Thomson Reuters Trust Principles.